Novartis India Limited (500672) Fair Value & Analysis
Other · IN · Market cap ₹15.2B
Fair value as of: Jul 4, 2026
From 22 valuation models · updated today
Share price +10.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹759.30 – ₹1,555 · fair‑value band ₹720.03 – ₹1,518 · the ₹1,469 price screens above the ₹834.73 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Novartis India Limited (500672) currently trades at ₹1,469, while our model-based Fair Value estimate is ₹834.73 — implying the stock looks roughly 43.2% overvalued today. We read business quality at 73/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
The stock trades on a trailing P/E of 151.8. Fundamentals as of Jul 4, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Novartis India Limited manufactures and sells healthcare products in India and internationally. The company offers a portfolio of prescription medicines in the areas of bone and pain, calcium portfolio, gynecology and neurosciences, oncology, primary care, and specialty medicines through healthcare professionals. It also provides generics products primarily focused on the therapeutic segments, such as anti-TB, anti-DUB, antihistamines, oncology, injectables, antibiotics, anti-ulcerants, anti-diabetes, and cardiovascular. In addition, the company offers eye care products. The company was founded in 1947 and is based in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Novartis India Limited reported revenue of ₹3.5B in FY2026 versus ₹4.0B in FY2022, a compound −3.0%/yr. Reported net income was ₹932M in FY2026.
Is 500672 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €209.16 | -60% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $28.75 | +71% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Novartis India Limited (500672) undervalued?
What is the fair value of 500672?
What is the quality score of 500672?
What is the net profit margin of 500672?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.